Case
|
Dose of peptide (mg)
|
Age
|
Sex
|
PS
|
Site of desease
|
Previous treatment*
|
IFN γ response to each peptide
|
Number of vaccination
|
Period of vaccinations (days)
|
Toxicity
|
Response
|
Prognosis (days)
|
Treatments after vaccination
|
---|
R
|
T
|
K
|
R1
|
R2
|
Injection site reaction
|
General
|
PFS
|
OS
|
---|
Pre vaccinations
|
---|
Within 3 courses of vaccinations
|
---|
Within 6 courses of vaccinations
|
---|
1
|
0.5
|
56
|
M
|
0
|
LN
|
IRI, OX, FU
|
++
|
–
|
–
|
–
|
–
|
85
|
2150
|
2
|
None
|
CR
|
2150
|
2150
|
A
|
None
|
–
|
–
|
+
|
++
|
–
|
+
|
++
|
+
|
++
|
–
|
2
|
0.5
|
72
|
F
|
1
|
Lung, bone
|
IRI, OX, FU
|
–
|
–
|
–
|
–
|
–
|
16
|
120
|
1
|
None
|
PD
|
60
|
191
|
D
|
None
|
+
|
–
|
–
|
–
|
+
|
+
|
+
|
–
|
–
|
+
|
3
|
0.5
|
75
|
M
|
1
|
Liver, lung
|
IRI, OX, FU
|
–
|
–
|
++
|
–
|
–
|
27
|
364
|
1
|
None
|
SD
|
158
|
406
|
D
|
OX, FU, BEV
|
++
|
–
|
–
|
–
|
+
|
++
|
–
|
+
|
–
|
+
|
4
|
1
|
59
|
F
|
2
|
Dissemi.
|
IRI, OX, FU
|
–
|
–
|
–
|
–
|
–
|
8
|
49
|
1
|
None
|
PD
|
36
|
80
|
D
|
None
|
++
|
–
|
–
|
–
|
–
|
++
|
–
|
+
|
–
|
+
|
5
|
1
|
68
|
M
|
0
|
Lung
|
IRI, OX, FU
|
–
|
–
|
–
|
–
|
–
|
25
|
329
|
2
|
None
|
PD
|
68
|
1009
|
D
|
OX, FU, IRI, BEV, CETU
|
++
|
+
|
++
|
+
|
++
|
++
|
+
|
++
|
+
|
++
|
6
|
1
|
69
|
M
|
2
|
Lung, LN
|
IRI, OX, FU
|
–
|
–
|
+
|
–
|
–
|
13
|
84
|
2
|
None
|
PD
|
62
|
110
|
D
|
None
|
–
|
++
|
–
|
–
|
–
|
–
|
++
|
–
|
–
|
–
|
8
|
3
|
85
|
F
|
1
|
Dissemi.
|
FU
|
–
|
–
|
–
|
–
|
–
|
11
|
70
|
2
|
None
|
PD
|
103
|
461
|
D
|
IRI, FU
|
–
|
–
|
–
|
+
|
–
|
–
|
–
|
–
|
+
|
–
|
9
|
3
|
59
|
M
|
0
|
Lung
|
IRI, OX, FU
|
+
|
–
|
–
|
–
|
–
|
45
|
777
|
2
|
None
|
SD
|
221
|
885
|
D
|
None
|
++
|
++
|
++
|
++
|
–
|
++
|
++
|
++
|
++
|
–
|
10
|
3
|
49
|
F
|
0
|
Liver, lung
|
IRI, FU
|
++
|
–
|
–
|
–
|
–
|
39
|
777
|
2
|
Fever <38.0°C
|
PD
|
69
|
834
|
D
|
OX, FU, IRI, BEV
|
+++
|
–
|
++
|
++
|
+
|
+++
|
–
|
++
|
++
|
+
|
11
|
3
|
46
|
F
|
0
|
Lung
|
none
|
–
|
–
|
–
|
–
|
–
|
13
|
64
|
2
|
Erythena (G1)
|
SD
|
117
|
1029
|
D
|
OX, FU, IRI, BEV
|
–
|
+
|
++
|
+++
|
++
|
–
|
+
|
++
|
+++
|
++
|
12
|
3
|
71
|
M
|
0
|
Local
|
OX, FU
|
–
|
–
|
–
|
–
|
–
|
63
|
959
|
2
|
None
|
SD
|
120
|
1059
|
D
|
IRI, FU, OX, BEV
|
+
|
++
|
++
|
–
|
+
|
+
|
++
|
++
|
+
|
+
|
13
|
3
|
71
|
M
|
2
|
Liver, lung, bone
|
IRI, OX, FU, RAD
|
–
|
–
|
–
|
–
|
–
|
8
|
49
|
1
|
None
|
PD
|
57
|
133
|
D
|
None
|
–
|
++
|
++
|
–
|
–
|
–
|
++
|
++
|
–
|
–
|
14
|
3 (mix)
|
65
|
F
|
2
|
Dissemi.
|
IRI, OX, FU
|
–
|
–
|
–
|
–
|
–
|
8
|
49
|
1
|
None
|
PD
|
50
|
342
|
D
|
None
|
+
|
+
|
++
|
+
|
++
|
+
|
+
|
++
|
+
|
++
|
15
|
3 (mix)
|
71
|
M
|
2
|
Liver, lung
|
IRI, OX, FU
|
–
|
–
|
–
|
–
|
–
|
8
|
49
|
1
|
None
|
PD
|
36
|
102
|
D
|
None
|
+
|
–
|
–
|
+++
|
++
|
+
|
–
|
–
|
+++
|
++
|
16
|
3 (mix)
|
57
|
M
|
1
|
Local
|
none
|
–
|
–
|
++
|
–
|
–
|
38
|
749
|
2
|
None
|
SD
|
771
|
1161
|
D
|
None
|
+
|
–
|
–
|
+++
|
+++
|
+
|
++
|
–
|
+++
|
+++
|
17
|
3 (mix)
|
65
|
M
|
1
|
Dissemi.
|
OX, FU
|
–
|
+
|
–
|
+++
|
–
|
16
|
126
|
2
|
None
|
PD
|
69
|
145
|
D
|
None
|
+
|
+
|
+
|
+++
|
+
|
+
|
+
|
+
|
+++
|
+
|
18
|
3 (mix)
|
55
|
F
|
0
|
Local
|
IRI, FU
|
–
|
+
|
+
|
–
|
–
|
8
|
49
|
2
|
None
|
SD
|
56
|
56
|
A
|
Curative resection
|
–
|
–
|
+
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
19
|
3 (mix)
|
58
|
F
|
2
|
Liver, Dissemi.
|
OX, FU, BEV
|
–
|
++
|
+
|
–
|
+
|
8
|
49
|
1
|
None
|
PD
|
37
|
52
|
D
|
None
|
++
|
+
|
++
|
–
|
+
|
++
|
+
|
++
|
–
|
+
|
- PS: Eastern Cooperative Oncology Group performance status, LN: lymph nodes, Dessemi: peritoneal dissemination, PFS: progression free survival, OS: over all survival.
- IRI: irinotican, OX: oxaliplatin, FU: fluoropyrimidine, RAD: radiation, BEV: bevacizumab, CETU: cetuximab, R: RNF43, T: TOMM34, K: KOC1, R1: VEGFR1, R2: VEGFR2, D: daed, A: alive.
- CR:complete response, PR: partial response, SD: stable desease, PD: progression desease, *: operation was performed for all patients for the resection of primary lesions.